Kairos Pharma, LTD. (KAPA) income statement
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.46+0.02 (+3.79%)
Close on Nov 19, 2026Market cap $1.70MP/E –Yield –
Kairos Pharma, LTD. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -98.0%
Financial strength
- Current ratio
- 6.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 631.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.44
- Dividend yield
- –
See a number that looks wrong?